Histogenics Corporation to Present at Upcoming Investor Conferences
February 23 2017 - 08:30AM
Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative
medicine company focused on developing and commercializing products
in the musculoskeletal space, today announced that Company
Management will be presenting at two upcoming healthcare investor
conferences.
- Cowen and Company 37th Annual Health Care Conference –
Boston, MA (March 6-8, 2017)Adam Gridley, Histogenics’
CEO, will be presenting a corporate overview on Monday, March 6,
2017, at 4:00 pm EST.
- Canaccord Genuity 2017 Musculoskeletal
Conference – San Diego (March 14,
2017)Adam Gridley, Histogenics’ CEO, will be presenting a
corporate overview on Tuesday, March 14, 2017 at 3:30 pm PST.
The conference immediately precedes the American Academy of
Orthopaedic Surgeons (AAOS) Annual Meeting and explores the current
state of orthopedics, biologics, imaging, robotic surgery, tissue
sculpting, and regenerative tissue companies.
The live webcasts for the presentations listed
above may be accessed by visiting the Investor Relations section of
Histogenics’ website at www.histogenics.com. The webcasts
will be available on Histogenics’ website for approximately 45 days
following the respective conferences.
About Histogenics
Corporation
Histogenics is a leading regenerative medicine
company developing and commercializing products in the
musculoskeletal segment of the marketplace. Histogenics’
regenerative medicine platform combines expertise in cell
processing, scaffolding, tissue engineering, bioadhesives and
growth factors to provide solutions to treat
musculoskeletal-related conditions. Histogenics’ first
investigational product candidate, NeoCart, is currently in Phase 3
clinical development. NeoCart is an autologous cell therapy
designed to treat cartilage defects in the knee using the patient’s
own cells. Knee cartilage defects represent a significant
opportunity in the United States, with an estimated 500,000 or more
applicable procedures each year. NeoCart is designed to
exhibit characteristics of articular, hyaline cartilage prior to
and upon implantation into the knee and therefore does not rely on
the body to make new cartilage, characteristics not exhibited in
other current treatment options. For more information, please
visit www.histogenics.com.
Contact:
Investor Relations
Tel: +1 (781) 547-7909
InvestorRelations@histogenics.com
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Mar 2023 to Mar 2024